Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Stability Indicating Validated Novel RP-HPLC Method for Dexlansoprazole and LC-MS/MS Study of Degradation Product

Article info

2023-04-29
2023-06-03
2024-03-01
81 - 106

Keywords

  • Validation
  • Stability Indicating
  • Dexlansoprazole
  • LC-MS/MS.
  • HPLC

Abstract

This work effectively developed and validated a stability-indicating RP-HPLC technique for precisely measuring dexlansoprazole in bulk samples. An Acetonitrile and 0.5 mmol Ammonium Acetate (pH 4.5) gradient mobile phase, a 1 ml/min flow rate, and detection at 283 nm were all part of the method's unique chromatographic conditions. A Kromasil C18 column was also used. Dexlansoprazole had a 5.14-minute retention period, and the tech-nique showed a linear range of 5–30 mg/ml with a strong correlation value of 0.997. The technique showed high sensitivity with a limit of detection (LOD) of 1.2 mg/ml and a limit of quantification (LOQ) of 3.64 mg/ml. The accuracy of the approach was shown by the per-centage recovery of dexlansoprazole, which varied from 98.6% to 102%. The International Council for Harmonisation (ICH) gave standards for validating the created approach, which were followed. It covered several variables: linearity, LOD, LOQ, accuracy, precision, ro-bustness, and solution stability. The technique demonstrated stability and the capacity to successfully separate the degradation products from the analyte peaks, establishing its validi-ty as a stability-indicating technique. LC-MS/MS spectra were also used to establish the degradants' structures.The quantitative measurement of dexlansoprazole in bulk form may be accomplished effectively using this established RP-HPLC technique. It is a useful instru-ment for quality control and stability evaluation of dexlansoprazole in pharmaceutical for-mulations because of its accuracy, precision, and stability-indicating capabilities.

Stability Indicating Validated Novel RP-HPLC Method for Dexlansoprazole and LC-MS/MS Study of Degradation Product

معلومات المقال

2023-04-29
2023-06-03
2024-03-01
81 - 106

الكلمات الإفتتاحية

  • Validation
  • Stability Indicating
  • Dexlansoprazole
  • LC-MS/MS.
  • HPLC

الملخص

This work effectively developed and validated a stability-indicating RP-HPLC technique for precisely measuring dexlansoprazole in bulk samples. An Acetonitrile and 0.5 mmol Ammonium Acetate (pH 4.5) gradient mobile phase, a 1 ml/min flow rate, and detection at 283 nm were all part of the method's unique chromatographic conditions. A Kromasil C18 column was also used. Dexlansoprazole had a 5.14-minute retention period, and the tech-nique showed a linear range of 5–30 mg/ml with a strong correlation value of 0.997. The technique showed high sensitivity with a limit of detection (LOD) of 1.2 mg/ml and a limit of quantification (LOQ) of 3.64 mg/ml. The accuracy of the approach was shown by the per-centage recovery of dexlansoprazole, which varied from 98.6% to 102%. The International Council for Harmonisation (ICH) gave standards for validating the created approach, which were followed. It covered several variables: linearity, LOD, LOQ, accuracy, precision, ro-bustness, and solution stability. The technique demonstrated stability and the capacity to successfully separate the degradation products from the analyte peaks, establishing its validi-ty as a stability-indicating technique. LC-MS/MS spectra were also used to establish the degradants' structures.The quantitative measurement of dexlansoprazole in bulk form may be accomplished effectively using this established RP-HPLC technique. It is a useful instru-ment for quality control and stability evaluation of dexlansoprazole in pharmaceutical for-mulations because of its accuracy, precision, and stability-indicating capabilities.

Why should you
Publish With Us?
An-Najah National University
Nablus, Palestine
P.O. Box
7, 707
Fax
(970)(9)2345982
Tel.
(970)(9)2345560
(970)(9)2345113/5/6/7-Ext. 2628
E-mail
[email protected]
EIC
Prof. Waleed Sweileh

The Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) © 2024 by An-Najah University, Nablus, Palestine is licensed under CC BY-NC 4.0